NPM1 and acute myeloid leukemia: Due to the large proportion of AML patients exhibiting NPM1-mutations, targeting NPM1 is a constant and ongoing area of research, and the wide variety of drugs available are dependent on the types of co-mutations present in NPM1-mutants.